Quantcast

Posts related to ‘Pharmaceuticals’

Sanofi, Regeneron Get Positive News from Drug Trials (SNY, REGN)

Posted: March 26, 2012 at 11:51 am

An anti-cholesterol drug being co-developed by Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) has shown positive results in two Phase II trials the companies reported this morning. The ...
Read Full Story »

Arena Files for European Drug Review (ARNA, VVUS, OREX)

Posted: March 26, 2012 at 10:42 am

Drug maker Arena Pharmaceuticals Inc. (NASDAQ: ARNA) announced that its application to sell its lorcaserin weight-loss drug in Europe has been accepted by the Europe Medicines Agency. This is the ...
Read Full Story »

AstraZeneca Loses Patent Fight (AZN)

Posted: March 26, 2012 at 7:36 am

Late last Friday, drug maker AstraZeneca PLC (NYSE: AZN) lost its court fight to prevent a generic version of its anti-psychotic drug Seroquel from reaching the US market. The company ...
Read Full Story »

Dendreon Rises on Takeover Chatter (DNDN, LLY, AMGN)

Posted: March 21, 2012 at 12:46 pm

Dendreon Corp. (NASDAQ: DNDN), maker of prostate cancer drug Provenge, is once again rumored to be a takeover target. As Streetinsider.com points out, the company’s new chairman presided over the ...
Read Full Story »

Targacept Slammed on Failed Drug Trial (TRGT, AZN)

Posted: March 20, 2012 at 12:44 pm

Drug developer Targacept Inc. (NASDAQ: TRGT) and partner AstraZeneca plc (NYSE: AZN) today announced that they will not file for regulatory approval on an anti-depressant drug called TC-5214 following a ...
Read Full Story »

The Generic Boniva Opportunity (RHHBY, MYL)

Posted: March 19, 2012 at 4:02 pm

The Food and Drug Administration approval of the first generic versions of osteoporosis drug Boniva won't be the end of Roche Holding AG (OTC: RHHBY) for its marketing of Boniva in the ...
Read Full Story »

Biopharma Firm Crushed by Merck Deal Cancellation (CRME, MRK)

Posted: March 19, 2012 at 11:11 am

Canadian-based drug company Cardiome Pharma Corp. (NASDAQ: CRME) announced this morning that Merck & Co. Inc. (NYSE: MRK) has cancelled further development of an oral version of a Cardiome drug ...
Read Full Story »

VIVUS Scores FDA Backing For Qnexa Against Obesity (VVUS, OREX, ARNA)

Posted: February 22, 2012 at 4:36 pm

VIVUS, Inc. (NASDAQ: VVUS) is going to likely have a huge day on Thursday.  The FDA panel reviewing its Qnexa drug to treat obesity has voted overwhelmingly to offer FDA panel backing ...
Read Full Story »

Merck Close to 52-Week High After Earnings (MRK)

Posted: February 2, 2012 at 8:55 am

Merck & Company, Inc. (NYSE: MRK) is trading up after its earnings report.  With a high dividend yield of 4.4%, many investors are watching this despite a stance of little ...
Read Full Story »

Pfizer Sneaks By Earnings Estimates (PFE, MRK)

Posted: January 31, 2012 at 7:17 am

Pfizer, Inc. (NYSE: PFE) looks good on the surface on its earnings report for the fourth quarter, but the company's guidance may be getting in the way a bit.  The ...
Read Full Story »

FTC Sues To Block Omnicare/PharMerica Merger; Express/Medco Next? (OCR, PMC, MHS, ESRX, T)

Posted: January 27, 2012 at 5:31 pm

The Federal Trade Commission is suing to block the merger between Omnicare, Inc. (NYSE: OCR) and Pharmerica Corporation (NYSE: PMC), where Omnicare is seeking to acquire the rival pharmacy provider PharMerica.... It ...
Read Full Story »

Risks Abound In Express Scripts & Medco Merger (MHS, ESRX, T, CHSI, MNA)

Posted: January 19, 2012 at 3:04 pm

The Medco Health Solutions Inc. (NYSE: MHS) and Express Scripts Inc. (NASDAQ: ESRX) merger saga is one which may go down in the financial history books for one of the ...
Read Full Story »

Pharma Value Beyond The Patent Expiration Cliff (PFE, MRK, BMY, TEVA, AMGN, GSK)

Posted: January 11, 2012 at 1:37 pm

The tide of patent expirations that is washing over big pharmaceutical houses is cresting now and investors have begun looking forward to how these companies will deal with some sharp ...
Read Full Story »

Short Sellers Help Push Dendreon Higher

Posted: January 6, 2012 at 6:39 am

Dendreon (NASDAQ: DNDN) soared almost 40% in value, or $3.02 a share, in active trading on Thursday after announcing that fourth-quarter revenue from its Provenge prostate-cancer vaccine would exceed earlier ...
Read Full Story »

Morning Movers (MSHL, CSIQ, TRGT,PGNX, CIE)

Posted: December 20, 2011 at 10:20 am

There are several stocks trading more heavily than usual this morning, and also experiencing large gains or drops in share prices. These include Marshall Edwards Inc. (NASDAQ: MSHL), Canadian Solar ...
Read Full Story »